Melatonin secretion decreases with age, and the use of prostate-specific membrane antigen (PSMA)-targeted nanocarriers loaded with I125 radioactive particles and encapsulated siRNAs targeting APE1 (siAPE1) and melatonin for the treatment of PCa played a good role in tumor-targeted therapy (Liu et al., 2024). Here, FOLH1 is linked to neoplasm.